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Abstract: The outcome of patients with acute venous thromboembo-
lism (VTE) and abnormal platelet count (PlC) at baseline has not been
consistently studied. In real-world clinical practice, a number of patients
with abnormal PlC receive vitamin K antagonists (VKAs) to treat acute
VTE despite their higher risk of bleeding.
We used the Registro Informatizado de Enfermedad TromboEm-
bo´lica registry database to compare the rate of major bleeding in patients
receiving VKA for long-term therapy of acute VTE according to PlC
levels at baseline. Patients were categorized as having very low
(<100,000/mL), low (100,000–150,000/mL), normal (150,000–
300,000/mL), high (300,000–450,000/mL), or very high (>450,000/
mL) PlC at baseline.
Of 55,369 patients recruited as of January 2015, 37,000 (67%)
received long-term therapy with VKA. Of these, 611 patients (1.6%)
had very low PlC, 4006 (10.8%) had low PlC, 25,598 (69%) had normal
PlC, 5801 (15.6%) had high PlC, and 984 (2.6%) had very high PlC at
baseline. During the course of VKA therapy (mean, 192 days), there
were no differences in the duration or intensity (as measured by
international normalized ratio levels) of treatment between subgroups.
The rate of major bleeding was 3.6%, 2.1%, 1.9%, 2.1%, and 3.7%,
respectively, and the rate of fatal bleeding was 0.98%, 0.17%, 0.29%,
0.34%, and 0.50%, respectively. Patients with very low or very high PlCo have severe comorbidities.
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Consistent alteration of PlC values at baseline suggested a greater
frailty.
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Abbreviations: DVT = deep vein thrombosis, INR = international
normalized ratio, LMWH = low molecular weight heparin, MB =
major bleeding, PE = pulmonary embolism, PlC = platelet count,
RIETE = Registro Informatizado de Enfermedad TromboEmbo´lica,
VKA = vitamin K antagonist, VTE = venous thromboembolism.
INTRODUCTION
V enous thromboembolism (VTE) is a major health problem,with substantial morbidity and mortality. Reliable infor-
mation on the factors influencing the risk for major bleeding
appearing during the course of anticoagulant therapy may
facilitate better use of therapy by improving the selection of
patients in whom its benefit will likely outweigh the risk, and by
identifying those who may benefit from careful management.
A number of prognostic scores identified patients with
abnormal platelet count (PlC) to be at increased risk for major
bleeding during the course of anticoagulant therapy. Accord-
ingly, current guidelines on antithrombotic therapy suggest
caution when using long-term anticoagulant therapy in patients
with abnormal PlC at baseline.1–6 Certainly, many patients with
abnormal PlC may also have active cancer, and low molecular
weight heparin (LMWH) is the first choice of treatment in
cancer patients with VTE.7,8 In the real-world clinical practice,
a substantial proportion of these patients, however, receive in
fact long-term therapy with vitamin K antagonists (VKAs).
Vitamin K antagonists interfere with the coagulation cas-
cade through inhibition of different factors, have a low onset of
anticoagulant action, a long half-life, multiple food and drug
interactions, and a very narrow therapeutic window outside of
which the risk of recurrence or bleeding increases exponen-
tially. For all these reasons, the use of VKA is not recommended
in patients with a high risk of bleeding in which it is desirable as
an alternative treatment. A previous study of Registro Informa-
tizado de Enfermedad TromboEmbo´lica (RIETE) investigators
found a relationship between abnormal PlC and major bleeding
in patients with VTE receiving anticoagulant therapy with either
LMWH, VKA, or direct oral anticoagulants. This study did not
consider the different risk of bleeding associated with any
specific treatment. Moreover, the patients were followed up
for only 3 months.9
In this study, we aimed to analyze the influence of PlC at
baseline in patients receiving long-term VKA treatment for
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acute VTE. The primary end point was to evaluate the corre-
lation between PlC at baseline and major bleeding appearing in
patients treated with VKA for long-term therapy of VTE in real-
life clinical practice. The secondary end point was to correlate
PlC at baseline with the severity, the time course, and the site of
major bleeding.
PATIENTS AND METHODS
Population
The RIETE registry is an ongoing, multicenter, international
(Spain, Italy, France, Israel, Portugal, Germany, Switzerland,
Czech Republic, Macedonia, United States, Brazil, and Ecuador),
observational registry of consecutive patients with symptomatic,
objectively confirmed, acute VTE. It started in Spain in 2001, and
6 years later the database was translated into English with the aim
to expand the registry to other countries, ultimately allowing
physicians worldwide to use the database to select the most
appropriate therapy for their patients. Data from this registry have
been used to evaluate outcomes after acute VTE, such as the
frequency of recurrent VTE, bleeding and mortality, and risk
factors for these outcomes. As previously described,10 at each
participating center, a registry coordinator controlled the quality,
the internal validity, and the coherence of the data collection.
Coordinators or their staff members recorded the data from each
patient on a computer-based case report form. The database of
each analysis was controlled, and the information was transferred
online via a secure Web site to the study coordinating center
responsible for data management. Data quality was also mon-
itored by members of contract research organizations who com-
pared the data on medical records with the data transferred online
during period visits to participating hospitals.
Inclusion Criteria
Consecutive patients with symptomatic, acute deep vein
thrombosis (DVT), or pulmonary embolism (PE), confirmed by
objective tests (compression ultrasonography or contrast veno-
graphy for DVT; helical computed tomography scan or venti-
lation–perfusion lung scintigraphy for PE), were enrolled in
RIETE. Patients were excluded if they were currently partici-
pating in a therapeutic clinical trial with a blinded therapy. All
patients (or their relatives) provided written or oral consent for
participation in the registry, in accordance with local ethics
committee requirements. This analysis was approved by the
ethics committee of the Hospital Universitari Germans Trias i
Pujol (Badalona, Spain) and by the institutional review board of
NorthShore University Health System (Evanston, IL).
Physicians participating in the RIETE registry ensured that
eligible patients were consecutively enrolled. Data were
recorded on to a computer-based case report form at each
participating hospital and submitted to a centralized coordinat-
ing center through a secure Web site. The study coordinating
center assigned patients with a unique identification number to
maintain patient confidentiality and was responsible for all data
management. Data quality was regularly monitored electroni-
cally, including checks to detect inconsistencies or errors, which
were resolved by contacting the local coordinators. Data quality
was also monitored by periodic visits to participating hospitals
by contract research organizations that compared medical
records with the submitted data.
Giorgi-Pierfranceschi et alStudy Design
For this study, only patients receiving VKA for long-term
therapy of VTE were considered. Platelet count at baseline was
2 | www.md-journal.comobtained using a Coulter counter method. Patients were cate-
gorized as having very low (<100,000/mL), low (100,000–
150,000/mL), normal (150,000–300,000/mL), high (300,000–
450,000/mL), or very high (>450,000/mL) PlC. We choose a
cutoff value of 100,000/mL to identify patients with very low
PlC because Nieto et al showed in 2010 this value to be an
independent risk factor for fatal bleeding,5 and the upper value
of 450,000/mL from the definition of thrombocytosis.11 Inter-
mediate groups, with low and high PlC, were individuated
between the limits of normal range (150,000–300,000/mL)
and values of very low and very high PlC values (100,000–
150,000 and 300,000–450,000/mL, respectively). Patients with
normal PlC were used as reference, and their outcome was
compared with that in the other 4 subgroups. The outcomes for
this study were the rate of major bleeding and fatal bleeding
during follow-up. The time course of bleeding was reported
considering 3 periods of treatment: 1–30 days, 31–90 days, and
over 90 days. Fatal bleeding was defined as any death occurring
within 10 days of a major bleeding episode, in the absence of an
alternative cause of death. Major bleeding was defined as an
overt bleed that required a transfusion of 2 or more units of
blood, was retroperitoneal, spinal or intracranial, or was fatal.
Baseline Variables
The following parameters were recorded when the quali-
fying episode of VTE was diagnosed: patient’s sex, age, and
body weight and height; presence of coexisting conditions such
as chronic heart or lung disease; concomitant therapies; recent
(<30 days earlier) major bleeding; presence of risk factors for
VTE, including recent immobility, surgery, active cancer
[defined as newly diagnosed cancer or cancer that is being
treated (ie, surgery, chemotherapy, radiotherapy, support
therapy, or combined treatments)], hormonal therapy, preg-
nancy, puerperium, prior VTE and recent travel; and laboratory
data at baseline, including whole blood counts and serum
creatinine levels.
Treatment and Follow-Up
Patients were managed according to the clinical practice of
each participating hospital (ie, there was no standardization of
treatment). The type, dose, and duration of anticoagulant
therapy were recorded. Patients were followed up for at least
3 months in the outpatient clinic. During each visit, any signs or
symptoms suggesting VTE recurrences or bleeding compli-
cations were noted. Most outcomes were classified as reported
by the clinical centers. If the staff at the coordinating center,
however, were uncertain how to classify a reported outcome, a
central adjudicating committee reviewed that event.
Statistical Analysis
The significance of a number of clinical variables on the
rate of major bleeding and fatal bleeding in the course of follow-
up was tested by a x2 test for categorical variables, and a P value
<0.05 was considered statistically significant. Incidence rates
were calculated as cumulative incidence (events/100 patient-
years) and compared using the rate ratio.
RESULTS
As of January 2015, 55,369 patients had been enrolled in
Medicine  Volume 94, Number 47, November 2015RIETE: 27,085 presenting with PE (with or without concomi-
tant DVT) and 28,284 with DVT alone. In all, 37,000 patients
(67%) received long-term therapy with VKA. Of these, 611
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tic value of international normalized ratio (INR) (higher than 3)
Vepatients (1.6%) had very low PlC, 4006 (10.8%) had low PlC,
25,598 (69%) had normal PlC, 5801 (15.6%) had high PlC, and
984 (2.6%) had very high PlC. Patients with very low or low PlC
were more likely to be men, significantly older, and to have
cancer or renal insufficiency than those with normal PlC
(Table 1). Patients with high or very high PlC were more likely
to be women and significantly younger, to have recent major
bleeding, recent immobility or surgery, and cancer than those
with normal count.
Most patients in all subgroups were initially treated with
LMWH, with no differences in mean daily doses between
subgroups, except in patients with very low count, who received
slightly lower LMWH doses and more likely underwent vena
cava filter insertion than those in the other subgroups (Table 2).
During the course of VKA therapy (mean, 192 days), there were
no differences in the duration or intensity of treatment between
subgroups. There were no differences either in the rate of VTE
recurrences during the course of therapy, but patients with
abnormal PlC at baseline had a higher mortality rate
(Table 2). During the course of anticoagulant therapy with
VKA, the rate of major bleeding was 3.6% (P< 0.01), 2.1%,
1.9%, 2.1%, and 3.7% (P< 0.001), respectively (Table 2). The
rate of fatal bleeding was 0.98% (P< 0.01), 0.17%, 0.29%,
0.34%, and 0.50%, respectively (Fig. 1; Table 2).
Major bleeding occurred during the first month of therapy
in 54%, 47%, 38%, 44%, and 43%, respectively. Among
patients with normal PlC, 45% of major bleeds occurred after
the third month of treatment (Fig. 2; Table 3).
Medicine  Volume 94, Number 47, November 2015There were no differences according to site of bleeding in
each subgroup (Table 3). Fatal bleeds were more common in
patients with very low PlC (0.98%), most likely because of the
TABLE 1. Clinical Characteristics of the Patients, According to Pl
<100,000 100,000–150,000
Patients, N 611 4006
Clinical Characteristics
Age (years) 67 16z 69 15z
Sex (male) 361 (59%)z 2523 (63%)z
Body weight (kg) 75 16y 77 15
Initial VTE presentation
Pulmonary embolism 307 (50%) 2154 (54%)
Risk Factors for VTE
Cancer 136 (22%)z 552 (14%)z
Active chemotherapy 61 (10%)z 195 (4.9%)z
Metastatic cancer 48 (7.9%)y 137 (3.4%)
Surgery 37 (6.1%) 189 (4.7%)z
Immobility 4 days 101 (17%) 606 (15%)z
Estrogen therapy 17 (2.8%)y 91 (2.3%)z
Pregnancy or puerperium 2 (0.3%) 9 (0.2%)y
Long-term travel 10 (1.6%) 89 (2.2%)

None of the above 312 (51%)y 2499 (62%)z
Underlying Conditions
Chronic liver disease 20 (3.3%)z 38 (0.95%)z
Chronic heart failure 38 (6.2%) 267 (6.7%)
Chronic lung disease 74 (12%) 532 (13%)y
Recent major bleeding 17 (2.8%)z 35 (0.87%)
CrCl levels <30 mL/min 49 (8.0%)z 272 (6.8%)z
Anemia 260 (43%)z 923 (23%)
Comparisons between patients with abnormal platelet count versus those
CrCl¼ creatinine clearance levels, VTE¼ venous thromboembolism.
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.higher rate of active cancer and advanced cancer among patients
with very low PlC (Fig. 3). The rate of fatal bleeding among
patients with very high PlC, however, was similar to that in the
remaining subgroups. Finally, there were no differences among
subgroups in the duration of VKA treatment. An overtherapeu-
nous Thromboembolism, Vitamin K Antagonists and Platelet Countwas found at the time of bleeding in patients with very low and
in very high PlC (41% and 40%, respectively) (Fig. 4).
DISCUSSION
Our study analyzed the influence of an abnormal PlC at
baseline on outcome in VTE patients undergoing long-term
VKA therapy. A number of previous studies found that patients
with low PlC are at an increased risk for major and fatal
bleeding during the course of anticoagulant therapy. Hence,
VTE patients with low PlC present a particularly challenging
therapeutic dilemma because they are at increased risk for
bleeding if anticoagulation is prescribed, and for recurrent
VTE in the absence of treatment. In our study, patients cate-
gorized as having very low and very high PlC receiving VKA
therapy were a not negligible proportion and they had a
significant increased risk for major bleeding, describing a U-
shaped curve. Mild PlC disorders, even if nonstatistically
significant, confirmed the increased rate of bleeding and the
U-shaped trend. We, however, found additional differences
among subgroups in their severity, but not in time course or
site of bleeding. At variance with previously reported findings,9the rate of fatal bleeding was significantly higher in patients
with very low PlC, but not in the very high PlC subgroup.
Moreover, we found no differences in the site of bleeding, even
atelet Count at Baseline
150,000–300,000 300,000–450,000 >450,000
25,598 5801 984
65 18 62 19z 62 19z
12,861 (50%) 2284 (39%)z 413 (42%)z
77 16 74 16z 72 15z
13,507 (53%) 3063 (53%) 550 (56%)
2850 (11%) 766 (13%)z 160 (16%)z
763 (3.0%) 206 (3.6%) 46 (4.7%)
640 (2.5%) 189 (3.3%) 41 (4.2%)
1931 (7.5%) 868 (15%)z 249 (25%)z
4568 (18%) 1236 (21%)z 212 (22%)y
1396 (5.4%) 455 (7.8%)z 50 (5.1%)
148 (0.58%) 99 (1.7%)z 30 (3.0%)z
727 (2.8%) 129 (2.2%)y 8 (0.81%)z
14,445 (56%) 2450 (42%)z 313 (32%)z
107 (0.42%) 29 (0.50%) 9 (0.91%)

1725 (6.7%) 384 (6.6%) 74 (7.5%)
2978 (12%) 640 (11%) 109 (11%)
219 (0.86%) 113 (1.9%)z 49 (5.0%)z
1152 (4.5%) 266 (4.6%) 55 (5.6%)
5727 (22%) 2332 (40%)z 603 (61%)z
with normal counts:

P< 0.05; yP< 0.01; zP< 0.001.
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TABLE 2. Treatment and Clinical Outcome (Expressed as Number of Events/100 Patient-Years), According to Platelet Count at
Baseline
<100,000 100,000–150,000 150,000–300,000 300,000–450,000 >450,000
Patients, N 611 4006 25,598 5801 984
Initial Therapy
Unfractionated heparin 61 (10%) 364 (9.1%)y 1996 (7.8%) 508 (8.8%) 89 (9.0%)
LMWH 510 (83%)z 3528 (88%) 22,858 (89%) 5105 (88%)y 873 (89%)
LMWH doses (IU/kg/d) 177 38 180 37 181 37 181 38 182 39
DOACs 1 (0.16%) 0 10 (0.04%) 3 (0.05%) 0
Fondaparinux 14 (2.3%) 58 (1.4%) 459 (1.8%) 111 (1.9%) 12 (1.2%)
Thrombolytics 5 (0.82%) 34 (0.85%)

139 (0.54%) 25 (0.43%) 2 (0.20%)
Vena cava filter 24 (3.9%)z 53 (1.3%) 358 (1.4%) 89 (1.5%) 26 (2.6%)y
VKAs Therapy
Duration (mean daysSD) 275 305 304 363 301 351 281 322z 283 319
Duration (median days) 189 199 195 190 189
% of time INR levels <2.0 30% 27% 28% 30%y 32%y
% of time INR levels 2.0–3.0 48% 52% 51% 50% 47%

% of time INR levels >3.0 22% 21% 21% 20% 21%
Events During Therapy
PE recurrences 1.52 (0.66–3.01) 0.84 (0.57–1.20) 1.11 (0.97–1.26) 1.20 (0.91–1.56) 1.19 (0.58–2.18)
7 28 234 54 9
DVT recurrences 2.85 (1.58–4.75)

1.90 (1.47–2.41) 1.45 (1.30–1.62) 1.71 (1.35–2.12) 2.01 (1.17–3.24)
13 63 306 76 15
VTE recurrences 4.20 (2.60–6.43)

2.76 (2.24–3.38) 2.57 (2.36–2.80) 2.91 (2.44–3.45) 3.27 (2.15–4.79)
Major bleeding 4.77 (3.06–7.10)y 2.65 (2.14–3.25) 2.41 (2.21–2.62) 2.79 (2.33–3.32) 4.93 (3.52–6.72)z
22 (3.6%) 88 (2.1%) 509 (1.9%) 125 (2.1%) 37 (3.7%)
All-cause death 12.3 (9.38–16)z 4.93 (4.22–5.73)z 3.60 (3.36–3.87) 5.25 (4.61–5.95)z 5.32 (3.86–7.14)
57 166 768 237 41
Fatal PE recurrences 0.22 (0.01–1.06) 0.15 (0.05–0.33) 0.16 (0.11–0.22) 0.18 (0.08–0.34) –
1 5 34 8
Fatal bleeding 1.51 (0.66–2.98)y 0.18 (0.07–0.37) 0.36 (0.28–0.44) 0.44 (0.28–0.67) 0.65 (0.24–1.44)
6 (0.98%) 7 (0.17%) 76 (0.29%) 20 (0.34%) 5 (0.5%)
Comparisons between patients with abnormal platelet count versus those with normal counts:

P< 0.05; yP< 0.01; zP< 0.001.
DOACs¼ direct oral anticoagulants, DVT¼ deep vein thrombosis, INR¼ international normalized ratio, IU¼ international units, LMWH¼ low
molecular weight heparin, PE¼ pulmonary embolism, SD¼ standard devia
FIGURE 1. Rate of major bleeding and fatal bleeding according to
platelet count subpopulations. H¼high, L¼ low, N¼normal,
VH¼ very high, VL¼ very low. P<0.01; P<0.001.
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4 | www.md-journal.comthough in other studies intracranial hemorrhage was the major
cause of death associated with VKA treatment.12
In patients with very low PlC, we found a higher rate of
active and advanced cancer, and most studies reported a higher
incidence of hemorrhagic complications in patients with malig-
nancy during the course of oral anticoagulant therapy.13 These
findings could explain the higher rate of fatal bleeds in this
subgroup. The first period of anticoagulation is associated with
a higher rate of bleeding, probably because of the presence of
occult lesions unmasked at the beginning of anticoagulant
therapy, and to a less adequate dose adjustment in that period.13
In our cohort, the timing of bleeding did not differ significantly
among subgroups, but we observed that in patients with abnor-
mal PlC, over 40% of bleeds occurred within the first month
after VKA therapy was started, and in patients with very low
PlC the rate was 54%. Finally, there were no differences in the
duration of VKA treatment or INR values at the time of
hemorrhage. Overtherapeutic INR levels (higher than 3.0) were
most often represented, both in very low and very high PlC
subgroups, as previously reported.14,15
tion, VKAs¼ vitamin K antagonists, VTE¼ venous thromboembolism.Several studies have analyzed the relationship between
PlC and outcome, but they assumed this relationship to be linear
and divided the continuous PlC value arbitrarily at specific cut
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
FIGURE 2. Rate of bleeding according to timing and platelet count subpopulations. H¼high, L¼ low, N¼normal, VH¼ very high,
VL¼ very low. P<0.01; P<0.001.
TABLE 3. Major Bleeding During the Course of Anticoagulation With Vitamin K Antagonist Drugs, According to Platelet Count at
Baseline
<100,000 100,000–150,000 150,000–300,000 300,000–450,000 >450,000
Major bleeding, N 22 88 509 125 37
Time Course of Bleeding,
First 30 days 12 (54%) 41 (47%) 193 (38%) 55 (44%) 16 (43%)
From day 31 to day 90 4 (18%) 16 (18%) 94 (18%) 24 (19%) 9 (24%)
From day 91 on 6 (27%) 33 (37%) 228 (45%) 48 (38%) 12 (32%)
INR Levels at Bleeding
<2.0 3 (14%) 29 (33%) 150 (29%) 35 (28%) 6 (16%)
2.0–3.0 7 (32%) 28 (32%) 115 (23%) 44 (35%)y 8 (22%)
>3.0 9 (41%) 21 (24%) 160 (31%) 35 (28%) 15 (40%)
Not available 3 (14%) 10 (11%) 84 (16%) 11 (8.8%)

8 (22%)
Sites of Major Bleeding
Gastrointestinal 8 (36%) 32 (36%) 170 (33%) 45 (36%) 12 (32%)
Intracranial 6 (27%) 16 (18%) 121 (24%) 23 (18%) 5 (13%)
Hematoma 2 (9.1%) 19 (22%) 103 (20%) 24 (19%) 8 (22%)
Retroperitoneal 1 (4.5%) 6 (6.8%) 37 (7.3%) 10 (8.0%) 3 (8.1%)
Urinary 1 (4.5%) 8 (9.1%) 29 (5.7%) 9 (7.2%) 0
Menorrhagia 0 0 14 (2.7%) 5 (4.0%) 4 (11%)

Hemoptysis 2 (9.1%)

0 7 (1.4%) 2 (1.6%) 0
Epistaxis 1 (4.5%) 0 8 (1.6%) 1 (0.80%) 0
Hemothorax 0 1 (1.1%) 5 (0.98%) 1 (0.80%) 1 (2.7%)
Hemopericardium 0 1 (1.1%) 2 (0.39%) 3 (2.4%) 0
Other 1 (4.5%) 5 (5.7%) 21 (4.1%) 5 (4.0%) 4 (11%)
30-Day Outcome
Recurrent PE 0 3 (3.4%) 6 (1.2%) 0 0
Recurrent DVT 0 2 (2.3%) 14 (2.7%) 1 (0.80%) 0
Major rebleeding 1 (4.5%) 5 (5.7%) 16 (3.1%) 2 (1.6%) 1 (2.7%)
Overall death 6 (27%) 12 (14%) 102 (20%) 26 (21%) 6 (16%)
Fatal PE 0 0 2 (0.39%) 0 0
Fatal bleeding 6 (27%) 7 (7.9%) 76 (15%) 20 (16%) 5 (13%)
Comparisons between patients with abnormal platelet count versus those with normal counts:

P< 0.05; yP< 0.01; zP< 0.001.
DVT¼ deep vein thrombosis, INR¼ international normalized ratio, PE¼ pulmonary embolism.
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Giorgi-Pierfranceschi et al Medicine  Volume 94, Number 47, November 2015points.16,17 In 2013, RIETE investigators showed that a PlC
lower than 100,000/mL is an independent predictor for fatal
bleeding in patients on anticoagulant therapy for acute VTE,
and it represents an item of the RIETE score for fatal bleeding.5
Furthermore, a number of studies reported the influence of
increased PlC on the rate of symptomatic VTE and outcome in
cancer patients,19,20 whereas a previous study in patients with
essential thrombocytopenia found a U-shaped curve for the
correlation between PlC and major bleeding (MB).21 Consistent
with our results, the previous findings from RIETE investigators
reported a statistically significant increased risk of MB in
FIGURE 3. Rate of active or metastatic cancer and active chemoth
N¼normal, VH¼ very high, VL¼ very low. P<0.01; P<0.001patients with low or high PlC and treated with different antic-
oagulant drugs for acute VTE,9 but our findings do not confirm
a statistically significant higher rate of fatal bleeding in very
FIGURE 4. International normalized ratio at time of bleeding accordin
NA¼not available, VH¼ very high, VL¼ very low. P<0.01; P<0
6 | www.md-journal.comhigh PlC subgroup. Furthermore, our study showed that altered
PlC at baseline was associated with important comorbidities,
such as severe renal impairment, active cancer, recent bleeding
complication, and anemia (Table 1). Thus, it is difficult to
declare whether an altered PlC at baseline should be considered
a risk factor for bleeding complications and mortality, or if these
poor outcomes could be influenced by many comorbidities and
a greater frailty in a patient presenting acute VTE and abnormal
PlC at baseline.
Our study has some limitations. Firstly, the study design
does not allow to prove the causality of relationship between
py according to platelet count subpopulations. H¼high, L¼ low,MB and altered PlC. Secondly, concerning the platelets count’s
monitoring, because of a lack in prospective values of PlC after
the index event. We have no data about PlC at the time of
g to platelet count subpopulations. H¼high, L¼ low, N¼normal,
.001.
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
Manolis Papadakis (Greece).
Vebleeding. In our database, we have no information about the
causes of abnormal PlC, probably because of cancer or che-
motherapy in thrombocytopenic patients, and secondary to
infection, inflammation, iron deficiency, tissue damage, hemo-
lysis, severe exercise, malignancy, or other causes11 in most
patients with thrombocytosis.
Moreover, previous studies showed that the presence of
extreme thrombocytosis might be associated with acquired von
Willebrand syndrome causing an increased risk of bleeding,22,23
but this hypothesis cannot be confirmed for all patients reported
in the RIETE registry because they are selected after a recent
VTE and not for chronic platelets’ disorders. Furthermore, we
have no data on the presence of liver cirrhosis, which could
cause thrombocytopenia and potentiates the response to VKA
therapy by impairing coagulation and making INR control
difficult,11 because in our cohort we recorded generically
chronic liver diseases. And lastly, on the anticoagulation side,
we have only partial data on INR at bleeding time (Fig. 4) that is
well known to be less predictive for hemorrhages than the time
in therapeutic range used to evaluate the intensity of antic-
oagulation.24
CONCLUSIONS
In summary, in patients with a recent VTE recorded in the
RIETE registry, we found a nonlinear, U-shaped, relationship
between PlC at baseline and major bleeding in patients on long-
term therapy with VKA for acute VTE. Patients with consist-
ently abnormal PlC had a number of comorbidities, such as
metastatic cancer, renal insufficiency, chronic liver disease,
anemia, recent major bleeding, and a greater mortality, thus
suggesting that a very low or very high PlC at baseline might be
a sign of greater frailty. Our findings may be of help to identify
patients who require closer surveillance on risk of bleeding, but
further dedicated studies are needed to evaluate the causality of
these relationships.
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